73 Drugs Losing Europe Exclusivity in 2024

In Europe, 2024 marks the year when exclusivity for a diverse range of drugs encompassing various therapeutic categories is set to expire. This includes established medications like Cabometyx and Zavicefta and breakthrough treatments like Tagrisso. 

The article provides a list of 73 such drug patents across diverse therapeutic categories, ranging from antivirals to antineoplastics, reflecting the broad impact of data exclusivity expiration. Whether it’s the widely used Epclusa for hepatitis C or the groundbreaking Venclyxto for chronic lymphocytic leukemia, the expiration signals a paradigm shift in market dynamics across various medical fields by improving access to essential treatments and stimulating innovation.

This is where Elixir comes into play.

Elixir equips generic leaders with a detailed list of expiring drug patents along with regulatory updates and market activities. With this information, companies can strategically plan market entries, navigate regulatory processes efficiently, optimize production, gain a competitive edge, and ensure timely market access for cost-effective alternatives.

See Elixir in action. 

73 Drug Patents Exclusivity Expiring in 2024

Medicine nameTherapeutic areaData Exclusivity Expiration dateMarketing authorization holder/company name
CabometyxCarcinoma, Renal Cell; Carcinomas, Hepatocellular9-Sep-2024Ipsen Pharma
NordimetArthritis, Psoriatic; Psoriasis; Arthritis, Juvenile Rheumatoid; Arthritis, Rheumatoid18-Aug-2024Nordic Group B.V.
Bortezomib HospiraMultiple Myeloma22-Jul-2024Pfizer Europe MA EEIG
RekovelleAnovulation12-Dec-2024Ferring Pharmaceuticals A/S
SomaKit TOCNeuroendocrine Tumors; Radionuclide Imaging8-Dec-2024Advanced Accelerator Applications
ZaviceftaPneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections23-Jun-2024Pfizer Ireland Pharmaceuticals
GlyxambiDiabetes Mellitus, Type 211-Nov-2024Boehringer Ingelheim International GmbH
EpclusaHepatitis C, Chronic6-Jul-2024Gilead Sciences Ireland UC
StrimvelisSevere Combined Immunodeficiency26-May-2024Fondazione Telethon ETS
IdelvionHemophilia B11-May-2024CSL Behring GmbH
BenepaliArthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis13-Jan-2024Samsung Bioepis NL B.V.
NeparvisHeart Failure26-May-2024Novartis Europharm Limited
LonsurfColorectal Neoplasms25-Apr-2024Les Laboratoires Servier
NinlaroMultiple Myeloma21-Nov-2024Takeda Pharma A/S
Amlodipine / Valsartan MylanHypertension22-Mar-2024Mylan Pharmaceuticals Limited
TagrissoCarcinoma, Non-Small-Cell Lung1-Feb-2024AstraZeneca AB
Emtricitabine/Tenofovir disoproxil MylanHIV Infections16-Dec-2024Mylan Pharmaceuticals Limited
InhixaVenous Thromboembolism15-Sep-2024Techdow Pharma Netherlands B.V. 
KovaltryHemophilia A18-Feb-2024Bayer AG
KisplyxCarcinoma, Renal Cell25-Aug-2024Eisai GmbH
Ivabradine ZentivaAngina Pectoris; Heart Failure11-Nov-2024Zentiva, k.s.
Tenofovir disoproxil ZentivaHIV Infections15-Sep-2024Zentiva k.s.
MysildecardHypertension, Pulmonary15-Sep-2024Viatris Limited
Emtricitabine/Tenofovir disoproxil KrkaHIV Infections9-Dec-2024KRKA, d.d., Novo mesto
OcalivaLiver Cirrhosis, Biliary12-Dec-2024ADVANZ PHARMA Limited
SialanarSialorrhea15-Sep-2024Proveca Pharma Limited
Zonisamide MylanEpilepsy31-Mar-2024Mylan Pharmaceuticals Limited
IbranceBreast Neoplasms9-Nov-2024Pfizer Europe MA EEIG 
EmplicitiMultiple Myeloma11-May-2024Bristol-Myers Squibb Pharma EEIG
Armisarte (previously Pemetrexed Actavis)Carcinoma, Non-Small-Cell Lung; Mesothelioma18-Jan-2024Actavis Group PTC ehf
QternDiabetes Mellitus, Type 2; Diabetes Mellitus; Nutritional and Metabolic Diseases; Metabolic Diseases; Glucose Metabolism Disorders15-Jul-2024Astra Zeneca AB
Emtricitabine/Tenofovir disoproxil ZentivaHIV Infections9-Nov-2024Zentiva k.s.
CinqaeroAsthma15-Aug-2024Teva B.V.
GalafoldFabry Disease25-May-2024Amicus Therapeutics Europe Limited
Lopinavir/Ritonavir MylanHIV Infections14-Jan-2024Mylan Pharmaceuticals Limited
NeofordexMultiple Myeloma16-Mar-2024THERAVIA
Atazanavir MylanHIV Infections22-Aug-2024Mylan Pharmaceuticals Limited
Eptifibatide AccordMyocardial Infarction11-Jan-2024Accord Healthcare S.L.U.
WakixNarcolepsy31-Mar-2024Bioprojet Pharma
GranpidamHypertension, Pulmonary14-Nov-2024Accord Healthcare S.L.U.
Briviact (in Italy: Nubriveo)Epilepsy13-Jan-2024UCB Pharma SA
DarzalexMultiple Myeloma20-May-2024Janssen-Cilag International N.V.
Rasagiline MylanParkinson Disease4-Apr-2024Mylan Pharmaceuticals Limited
TaltzPsoriasis25-Apr-2024Eli Lilly and Company (Ireland) Limited
VaxelisMeningitis, Haemophilus; Poliomyelitis; Tetanus; Diphtheria; Whooping Cough; Hepatitis B15-Feb-2024MCM Vaccine B.V.
OdefseyHIV Infections21-Jun-2024Gilead Sciences Ireland UC
DescovyHIV Infections21-Apr-2024Gilead Sciences Ireland UC
VenclyxtoLeukemia, Lymphocytic, Chronic, B-Cell4-Dec-2024AbbVie Deutschland GmbH Co. KG
FlixabiArthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid; Crohn Disease; Psoriasis26-May-2024Samsung Bioepis NL B.V.
CoagadexFactor X Deficiency16-Mar-2024BPL Bioproducts Laboratory GmbH
OncasparPrecursor Cell Lymphoblastic Leukemia-Lymphoma14-Jan-2024Les Laboratoires Servier
Onivyde pegylated liposomal (previously known as Onivyde)Pancreatic Neoplasms14-Oct-2024Les Laboratoires Servier
FeraccruAnemia, Iron-Deficiency18-Feb-2024Norgine B.V.
ZepatierHepatitis C, Chronic22-Jul-2024Merck Sharp & Dohme B.V.
Pemetrexed AccordCarcinoma, Non-Small-Cell Lung; Mesothelioma18-Jan-2024Accord Healthcare S.L.U.
Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune)Influenza, Human20-May-2024AstraZeneca AB
Tenofovir disoproxil MylanHIV Infections8-Dec-2024Mylan Pharmaceuticals Limited
Pemetrexed Fresenius KabiCarcinoma, Non-Small-Cell Lung; Mesothelioma22-Jul-2024Fresenius Kabi Deutschland GmbH
UptraviHypertension, Pulmonary12-May-2024Janssen Cilag International NV
OngentysParkinson Disease24-Jun-2024Bial – Portela Cª, S.A.
Letifend20-Apr-2024LETI Pharma, S.L.U.
Sedadex12-Aug-2024Le Vet Beheer B.V.
Palonosetron AccordVomiting; Nausea; Cancer26-May-2024Accord Healthcare S.L.U.
Cepedex13-Dec-2024CP-Pharma Handelsgesellschaft mbH
AlprolixHemophilia B12-May-2024Swedish Orphan Biovitrum AB (publ)
Halagon13-Dec-2024Emdoka BVBA
ParsabivHyperparathyroidism, Secondary11-Nov-2024Amgen Europe B.V.
Bortezomib SunMultiple Myeloma22-Jul-2024SUN Pharmaceutical Industries (Europe) B.V.
Eravac22-Sep-2024Laboratorios Hipra, S.A.
Sevohale (previously known as Sevocalm)21-Jun-2024Chanelle Pharmaceuticals Manufacturing Limited
Evalon18-Apr-2024Laboratorios Hipra, S.A.
EndolucinBetaRadionuclide Imaging6-Jul-2024ITM Medical Isotopes GmbH
SpectrilaPrecursor Cell Lymphoblastic Leukemia-Lymphoma14-Jan-2024Medac Gesellschaft fuer klinische Spezialpraeparate mbH

With the expiration of patents for 73 drugs in Europe in 2024, patients and healthcare providers will observe increased access to more affordable treatment options and an opportunity to enter previously inaccessible markets. Additionally, the post-exclusivity era will provide a new opportunity for further development and investment in research, leading to the creation of new, innovative formulations and delivery methods. 

Now that all the generic drug companies would jump on to the opportunity, the best way forward is to get a headstart with Elixir. 

Boost your chances of being the first to know which drugs’ patent exclusivity will expire this year and execute a successful launch of your generic drug manufacturing efforts.

Try Elixir today!

Authored by: Smiksha Sood, Product Development Team

Edited by: Annie Sharma

Leave a Comment

Become a part of GreyB’s insider list

Get our distilled learning delivered to you.

Get the Sample Report

Fill out the form and get the report.